With the extensive experience and scientific teams in CAR-T therapy, Creative Biolabs is fully competent and dedicated to our end-to-end CAR-MA therapy solutions for worldwide clients. You can start at any module or choose end-to-end integrated service to best fit your projects within budget requirements.
Chimeric Antigen Receptor (CAR) Macrophage Cell Therapy Service
Creative Biolabs provides a suite of research services for Chimeric Antigen Receptor Macrophage (CAR-M) engineering. We provide specialized scFv optimization, signaling domain design, and high-efficiency cell modification tailored to your specific research targets. By utilizing our platform, clients gain access to high-potency myeloid effectors that demonstrate improved penetration in 3D tumor models and robust antigen-presentation capabilities. Our service enables researchers to evaluate complex immune interactions and validate therapeutic targets in advanced pre-clinical research settings.
Introduction What We Can Offer How We Can Help Why Choose Us? Customer Reviews FAQs Related Services Contact Us
CAR-MA Cell Therapy - Next Generation Cellular Therapy Targeting Solid Tumors
As a key component in tumor microenvironment, macrophages are actively recruited into tumors and therefore they can be called as tumor-associated macrophages (TAMs). Based on plasticity, macrophages can be divided into classical M1 and alternative M2 type. TAMs closely resemble the M2 type which can accelerate tumor progression. Hence, CAR manipulation to resemble the M2 type into antitumor macrophage will be a promising novel strategy for cancer therapy. Comparing with CAR-T and CAR-NK therapy, CAR-MA owns the following advantages.
- Widely distributed throughout the body;
- Survive in hypoxic and nutrition deficient tumor microenvironment;
- Capability to present antigen as an APC to stimulate adaptive immunity.
Request a Consultation →
Fig.1 CAR-Ms represent a promising frontier in immunotherapy. 1
What We Can Offer
Creative Biolabs has developed an innovative and proprietary platform for next-generation CAR-engineered cell therapies (CAR-Macrophage) with great therapeutic potential for solid tumor. Our unique and proprietary CAR-MA platform is utilized to manufacture CAR-MA therapies for a wide range of cancers, especially intractable solid tumors. Given to the special characteristics of macrophages, our approach is to use the macrophages isolated from the blood or THP1 macrophage model, and genetically engineer them to express a CAR to guide them to eat the malignant cells. Once CAR-MA preparation is completed, both in vitro assays and in vivo animal testing will be performed to evaluate the efficacy and safety aspects.
End-to-end CAR-MA Integrated Services
Neoantigen Identification
With multiple gene and protein analysis technologies, as well as expertise in potential targets with greater potency and lower toxicity, we offer unique de novo neoantigen discovery, identification, selection to get a suitable CAR-MA therapy target.
Learn More →scFv Generation and Optimization
Empowered by our well-established in-house antibody database and various types of libraries, plus scFv sequencing and affinity measurement platforms, we are committed to generating the optimized scFv with high affinity and good characteristics.
Learn More →CAR Design & Construction
Sharing the similar components and characteristics of CAR design for CAR-T and CAR-NK, we offer customized CAR design for CAR-macrophage purpose. Specific considerations will be included to fit the needs of macrophage signaling transduction.
Learn More →CAR-MA Preparation
Given the specific properties of macrophages, to avoid macrophage polarized to the immunosuppressive, pro-tumor phenotype, we developed a unique transfection technology to ensure efficient CAR-MA preparation with desirable anti-tumor phenotype.
Learn More →CAR-MA In Vitro Validation
For generated CAR-MA product, a broad range of in vitro assays are available to assess the MA function such as CAR expression validation, quantitative phagocytosis and luciferase-based specific killing assays, etc.
CAR-MA In Vivo Testing
After in vitro assays, a series of in vivo testing will be performed in cancer xenograft models to evaluate the pharmacology and toxicology aspects of CAR-MA product.
Let Creative Biolabs Support Your CAR-T Therapy Breakthrough
Fig.2 The main cellular sources and genetic modification approaches used to generate CAR-Ms. 1
Highlights
Creative Biolabs leads in myeloid engineering for research. Our unique capabilities provide a significant advantage for your pre-clinical development through four key pillars:
Integrated Research Solutions
We provide seamless end-to-end laboratory support from early discovery to validation, ensuring highly streamlined development for your complex myeloid-based research projects within our facilities.
Enhanced Effector Potency
Our dual-signaling constructs and technology deliver cell models with superior phagocytic activity and improved persistence to effectively tackle challenging solid tumor models.
Safety & Knowledge
We prioritize research-level safety with minimal model toxicity while leveraging our deep expertise in diverse solid tumor types and microenvironments for accurate data.
Optimized Myeloid Scalability
Our transition to specialized CAR-MA platforms offers a notable increase in circulation half-life, improving the overall scalability and reliability of laboratory results.
To receive a detailed technical assessment and see how our tailored CAR-M solutions can overcome your specific research bottlenecks - Get a Quote
Customer Reviews
-
Enhanced Phagocytic Potency
Using Creative Biolabs' CAR-M technology in our research has facilitated our understanding of extracellular matrix degradation in pancreatic cancer models. The CD147-integrated constructs showed remarkable remodeling capabilities. - Dr. A**a. G. -
Superior Phenotypic Stability
The TIR-domain signaling architecture provided by Creative Biolabs ensured our engineered macrophages remained in the M1 state even after exposure to TGF-β rich environments in our laboratory assays. - Prof. Z***n. C.
FAQs
How does CAR-M compare to CAR-T in research models?
CAR-M cells possess intrinsic matrix-degrading enzymes that allow them to penetrate dense stroma in 3D models where T-cells cannot. They also provide a different cytokine profile for studying innate immune responses.
How do you ensure the macrophages don't turn into pro-tumor states in models?
We incorporate specialized co-stimulatory domains (like TLR/TIR) and use research-grade polarization factors to lock the cells in a pro-inflammatory M1 phenotype for the duration of the study.
Related Services
CAR-T Cell Design & Manufacturing
Precision engineering of T-cell receptors to recognize intracellular tumor antigens presented by HLA molecules in advanced oncology models.
Learn More →CAR NK Cell Design & Manufacturing
Innovative platforms for generating off-the-shelf natural killer cells with customized receptors for high-potency research into MHC-independent tumor killing.
Learn More →How to Contact Us
Supported by our multidisciplinary team with flexible solutions, the specific properties of your CAR-MA product will be tailored and flexible customized integration solutions will be provided. Creative Biolabs pioneered the development of CAR-MA platform for the delivery of CAR-MA based medicines that fulfills the stringent requirements of clinical purpose. We are committed to making cell and gene therapy a reality. For detailed information, please contact us to know more.
Reference
- Alrehaili, Maram et al. "CAR-macrophages in solid tumors: promise, progress, and prospects." NPJ precision oncology vol. 9,1 382. 27 Nov. 2025. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.1038/s41698-025-01170-7
Download our brochureLoading case studies...
Online Inquiry